SCHEMBL20093467

SCHEMBL20093467

Nc1ncnc2[nH]nc(-c3cccc(C(=O)N4CCOCC4)c3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.52
PLK4 O00444 1/20 0.52
MAP4K4 O95819 1/20 0.52
ROS1 P08922 1/20 0.52
FGFR1 P11362 1/20 0.52
FLT1 P17948 1/20 0.52
MARK3 P27448 1/20 0.52
FLT4 P35916 1/20 0.52
KDR P35968 1/20 0.52
FLT3 P36888 1/20 0.52
CLK2 P49760 1/20 0.52
CSNK1G2 P78368 1/20 0.52
MAP4K2 Q12851 1/20 0.52
ROCK1 Q13464 1/20 0.52
NTRK3 Q16288 1/20 0.52
MINK1 Q8N4C8 1/20 0.52
AURKB Q96GD4 1/20 0.52
PRKD2 Q9BZL6 1/20 0.52
CLK4 Q9HAZ1 1/20 0.52
MAP4K5 Q9Y4K4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23917237 0.80 MAP2K4 (0.57) PLK4ROS1FGFR1FLT1MARK3
SCHEMBL130485 0.80 PIK3CA (0.57) KDRAURKBPIK3CAMTORATR
SCHEMBL23917241 0.79 PIK3CD (0.57) PLK4MAP4K4ROS1MARK3FLT4
SCHEMBL22276018 0.76 LRRK2 (0.55) MAP4K4KDRATRLRRK2
SCHEMBL12343017 0.75 PLK4 (0.62) JAK2PLK4MAP4K4ROS1FGFR1
SCHEMBL3372400 0.75 PLK4 (0.59) JAK2PLK4MAP4K4ROS1FGFR1
SCHEMBL12343005 0.75 PLK4 (0.61) JAK2PLK4MAP4K4ROS1FGFR1
SCHEMBL12343043 0.74 JAK2 (0.60) JAK2PLK4MAP4K4ROS1FGFR1
SCHEMBL12343015 0.74 PLK4 (0.60) JAK2PLK4MAP4K4ROS1FGFR1
SCHEMBL13116124 0.73 JAK2 (0.59) JAK2PLK4MAP4K4ROS1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 JAK2 319/4885PLK4 365/4885MAP4K4 117/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B JAK2 355/4885PLK4 269/4885MAP4K4 119/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE JAK2 235/4885PLK4 338/4885MAP4K4 144/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB JAK2 290/4885PLK4 333/4885MAP4K4 129/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB JAK2 280/4885PLK4 433/4885MAP4K4 195/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 JAK2 360/4885PLK4 356/4885MAP4K4 87/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A JAK2 170/4885PLK4 595/4885MAP4K4 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.